Purpose: To describe a patient with a PITPNM3 missense mutation who developed lateonset autoimmune retinopathy.
A utoimmune retinopathy (AIR) is a rare condition where retinal antigens are targeted by the immune system leading to photoreceptor degeneration. It is characterized by vision loss, visual field deficits, photoreceptor dysfunction, and the presence of retinal autoantibodies. Autoimmune retinopathy can be further subdivided, based on etiology, into paraneoplastic AIR (pAIR) and nonparaneoplastic AIR (npAIR). 1,2 Paraneoplastic AIR encompasses both cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR). Nonparaneoplastic AIR, representing most AIR cases, is a diagnosis of exclusion which is typically made after neoplastic workup is presumably negative, and in the absence of genetic causes of retinal degeneration. The presence of retinal autoantibodies is an important surrogate measure that has been used to support the diagnosis of AIR. [1] [2] [3] [4] To date, there are no genetic mutations associated with a predisposition to AIR. Given the rarity of the condition, genetic linkage analysis is less feasible. Here, we report a case of an 85-year-old white man who experienced rapid deterioration in vision coupled with evidence of photoreceptor loss-of-function on electroretinogram (ERG) testing. Whole-exome sequencing revealed a significant heterozygous mutation in PITPNM3. A missense mutation in the PITPNM3 gene has been previously associated with autosomal dominant cone dystrophy 5 (CORD5). 5 Although our patient demonstrated rod-cone dystrophy, the rapid decline in vision in his ninth decade, along with the detection of retinal autoantibodies, raised the possibility of superimposed npAIR. Interestingly, this gene was previously reported to be necessary for regulatory T-lymphocyte (Tregs) infiltration in human breast cancer xenografts. 6 
Case Report
An 85-year-old man with a medical history of diabetes mellitus Type 2, hypertension, benign prostate hyperplasia, and 2 previous episodes of ischemic stroke presented with decreased vision after cataract surgery with a multifocal lens implant. His postoperative course was complicated by cystoid macular edema that was managed with topical NSAIDs and steroids. There was no significant family history. He complained of nyctalopia and photoaversion. On examination, visual acuity was 20/30 bilaterally with a decreased field of vision in the far periphery. Slit-lamp examination revealed clear cornea and an unremarkable anterior segment examination with no cells or flare. A multifocal intraocular lens was well centered. Posterior fundus examination revealed a clear vitreous and a scalloped pattern of atrophy in the left inferotemporal arcade. Mild pigmentary changes were present in the periphery of both eyes in the absence of bone spicules. Fundus autofluorescence highlighted the area of RPE scalloping and a ring of hyperautofluorescence in the perifoveal area (Figure 1 ). Spectral domain optical coherence tomography showed vitreomacular traction in the right eye and loss of the ellipsoid band, along with outer retinal atrophy, outside the fovea in both eyes (Figure 1 ). Full-field ERG (ffERG) was performed with a Diagnosys Espion Electrophysiology System (Diagnosys LLC, Lowell, MA) using Burian-Allen contact lens electrodes, with signal subsequently obtained through narrow band-passed filtering with computed averaging. Rod responses were extinguished and cone responses were severely attenuated bilaterally (Figure 2 ). The top differential diagnoses included pAIR, npAIR, and late-onset retinitis pigmentosa. An antiretinal autoantibody western blot performed at the Ocular Immunology Laboratory (Portland, OR) was positive for retinal autoantibodies against 20-kDa and 125-kDa proteins. Neoplastic workup performed by his primary care provider was unrevealing. Whole-exome sequencing at the Columbia University Medical Center Department of Pathology (New York, NY) revealed a heterozygous missense mutation in the PITPNM3 gene c.2579T.C, corresponding to a change in amino acid, Ile860Thr. A missense mutation in the PITPNM3 gene has been previously associated with autosomal dominant cone dystrophy 5 (CORD5). 5 To the best of our knowledge, no clinical phenotypes have been associated with the mutation c.[2579T.C]. Three months after presentation, the patient returned for a follow-up appointment with marked subjective deterioration in vision. He described severe constriction in his visual field. Photopic 30-Hz flicker ERG was performed using Ganzfeld stimulation and showed further reduction in the amplitude in the left eye (Figure 3) . A diagnosis of superimposed npAIR was made and the patient was started on immunosuppressive therapy.
Discussion
Autoimmune retinopathy is a rare entity with unclear etiology. Although the presence of circulating retinal antibodies is used as a surrogate measure in the diagnosis of AIR, their lack of specificity limits their usefulness. 4, [7] [8] [9] Retinal antibodies have been detected in 37% of patients with RP and in other retinal diseases. 10, 11 In our patient, 2 proteins were identified as retinal autoantibodies, corresponding to 20-kDa and 125-kDa bands on western blot. Their molecular weights do not correspond to retinal antibodies that are more specific to AIR, such as recoverin or enolase. [1] [2] [3] [4] In this case, a diagnosis of superimposed npAIR was made because of the rapid deterioration in vision rather than the presence of the retinal autoantibodies.
The patient also harbored a missense mutation in the PITPNM3, which has been implicated in CORD5. 5 Electroretinogram findings were more consistent with rod-cone dysfunction. The patient's initial clinical presentation could have been consistent with AIR or rodcone dystrophy, given the lack of inflammatory cells, the involvement of both rods and cones, the loss of outer retinal structures on spectral domain optical coherence tomography, the presence of a parafoveal hyperfluorescent ring on fundus autofluorescence, the cystoid changes in the macula, and the presence of patches of RPE mottling. 1, 12, 13 Given the presence of a likely pathogenic mutation in a gene implicated in retinal dystrophy, the diagnosis of AIR was not entertained initially. However, the rapid decline in vision, as also documented by electrophysiologic testing, raised the possibility of superimposed npAIR as a diagnosis. Cone-rod dystrophy inherited in an autosomal dominant fashion typically presents at an earlier age. 14 A rapid deterioration in vision over the course of few months is extremely uncharacteristic for late-onset cone-rod or rod-cone dystrophies. By definition, npAIR is a diagnosis of exclusion. Although in our patient neoplastic workup was negative, he should still be monitored for any signs of malignancy. pAIR has been reported to occur 11 years before cancer detection. 15 The patient had a missense mutation in PITPNM3, leading to a change in amino acid I860T. This novel mutation is different than the previously reported mutation Q626H, which is associated with CORD5 5 and to the best of our knowledge, has not been linked to any retinal dystrophy. The I860T mutation was present at the Exome Aggregation Consortium (ExAC) database at a very low frequency (3/ 105,948), with no homozygotes, indicating that it is likely more pathogenic than a normal variant. Bioinformatics analysis by PROVEAN predicted that the mutation is deleterious (PROVEAN score: −4.10). Interestingly, knockdown of PITPNM3, a chemokine ligand 18 (CCL 18) receptor, in a human breast cancer xenograft reduced the infiltration of regulatory T cells. 6 Regulatory T cells help modulate the immune system, by exerting an immune suppressive effect. Regulatory T cells were also shown to be present in the eye and may play an important role in maintaining its immune privileged environment. 16 We, thus, propose that a missense mutation in PITPNM3 may have predisposed the patient to AIR. Testing other family members for the mutation could help determine whether the patient had an underlying dystrophy that was complicated by AIR.
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